Genetic Technology Alert. Cancerous Growth Inhibited by a Kinase Inhibitor; Patient-Driven Oncological Therapeutic Solutions Using Cancer Genomic Foundation; Multiple Kinase Inhibitors Targeting Oncological Disorders Currently in Clinical Trials

USD 250

* Required Fields

USD 250

PAY BY INVOICE

Be the first to review this product

This issue profiles cancerous growth inhibited by a kinase inhibitor, patient-driven oncological therapeutic solutions using cancer genomic foundation, and multiple kinase inhibitors targeting oncological disorders that are currently in clinical trials.

Table of Contents

Genetic Technology Alert. Cancerous Growth Inhibited by a Kinase Inhibitor; Patient-Driven Oncological Therapeutic Solutions Using Cancer Genomic Foundation; Multiple Kinase Inhibitors Targeting Oncological Disorders Currently in Clinical TrialsIn This Issue1. CANCEROUS GROWTH INHIBITED BY A KINASE INHIBITOR2. PATIENT-DRIVEN ONCOLOGICAL THERAPEUTIC SOLUTIONS USING CANCER GENOMIC FOUNDATION3. MULTIPLE KINASE INHIBITORS TARGETING ONCOLOGICAL DISORDERS CURRENTLY IN CLINICAL TRIALS4. KEY PATENTS ACROSS KINASE INHIBITORS5. TECHVISION 2015




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 31-Oct-17

Region : Global

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.